Interestingly, the reduced activity of the signaling pathway converging on the transcription factor NFκB (Nuclear Factor κB), regarded as an anti-apoptotic and defense mechanism in the tumor cell, was only observed in certain studies on proteasome-inhibitor-treated GBM cells [14] and was not detected in others when the proteasome inhibitor was used as a single agent [27,28]. The gene discussed is NFKB1; the disease is glioblastoma.